Furthermore, findings from a phase II study combining pabolizumab and cabozantinib in treating recurrent/metastatic squamous cell carcinoma of the neck (R/M HNSCC) (NCT03468218) revealed that this mix was generally well-received, leading to a one-year PFS of 54% and OS of 68% in patients with assessable R/M HNSCC [143]
Nat Rev Mol Cell Biol 6 : 5668 Murray N, Salgia R, Fossella FV (2004) Targeted molecules in small cell lung cancer
Kridin K, Renert-Yuval Y, Guttman-Yassky E, Cohen AD (2020) Alopecia areata is associated with atopic diathesis: results from a population-based study of 51,561 patients
Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract
For example, Seattle Genetics (SGN)-LIV1A or ladiratuzumab vedotin (LV), is currently in clinical trials for metastatic BC